Ontology highlight
ABSTRACT: Background
Vonoprazan, a novel acid-suppressive drug, is non-inferior to proton pump inhibitors (PPIs) for the management of gastric acid-related diseases. However, the safety of vonoprazan has not been systematically evaluated yet.Objectives
To elucidate the incidence and type of adverse events (AEs) in patients taking vonoprazan.Design
Systematic review and meta-analysis.Data sources and methods
PubMed, EMBASE, and Cochrane Library databases were searched for all studies reporting the safety of vonoprazan. The incidences of any AEs, drug-related AEs, serious AEs, AEs leading to drug discontinuation, and common AEs were pooled. Odds ratios (ORs) were calculated to compare the incidence of AEs between patients taking vonoprazan and PPIs.Results
Seven
SUBMITTER: Xu W
PROVIDER: S-EPMC10126681 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature